Enliven Therapeutics (NASDAQ:ELVN) Director Sells $606,710.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director J. Scott Garland sold 13,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at approximately $606,710. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Enliven Therapeutics Trading Down 2.4%

NASDAQ ELVN opened at $41.36 on Thursday. The company has a market cap of $3.03 billion, a price-to-earnings ratio of -24.77 and a beta of 0.24. The company has a 50 day moving average of $54.63 and a 200-day moving average of $47.70. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. KBC Group NV acquired a new stake in Enliven Therapeutics in the first quarter valued at $38,000. State of Wyoming bought a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at about $96,000. FNY Investment Advisers LLC acquired a new stake in shares of Enliven Therapeutics in the second quarter valued at about $126,000. WINTON GROUP Ltd acquired a new stake in shares of Enliven Therapeutics in the second quarter valued at about $228,000. Finally, Squarepoint Ops LLC bought a new position in shares of Enliven Therapeutics during the second quarter worth about $259,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ELVN shares. Guggenheim dropped their target price on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Morgan Stanley started coverage on shares of Enliven Therapeutics in a research note on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price objective on the stock. Mizuho boosted their price objective on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. JPMorgan Chase & Co. initiated coverage on Enliven Therapeutics in a research note on Thursday, October 1st. They set an “overweight” rating and a $75.00 target price for the company. Finally, HC Wainwright raised their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $74.44.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.